Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 20/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186561 | 0.86 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL18195286 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL18186494 | 0.81 | HSD17B1 (0.68) | HSD17B1HSD17B2 | |
| SCHEMBL18186553 | 0.81 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL27605083 | 0.80 | MKNK1 (0.78) | HSD17B1HSD17B2 | |
| SCHEMBL18186509 | 0.80 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL18186564 | 0.78 | HSD17B1 (0.76) | HSD17B1HSD17B2 | |
| SCHEMBL18186555 | 0.77 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL18186441 | 0.77 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL18186496 | 0.77 | HSD17B1 (1.00) | HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| EP-3089969-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 | Elexopharm GmbH (DE) | 2016-11-09 | — | — | EP | claimed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | claimed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | HSD17B1, HSD17B2, HSD17B3 | HSD17B1 1/4885HSD17B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.